INLYTA® What is INLYTA?

(axitinib)

What is INLYTA?

•
in combination with avelumab or pembrolizumab as your first treatment.
•
alone when 1 prior drug treatment regimen for your RCC has not worked.

It is not known if INLYTA is safe and effective in children.

Before taking INLYTA, tell your healthcare provider about all of your medical conditions, including if you:

•
have high blood pressure
•
have thyroid problems
•
have liver problems
•
have a history of blood clots in your veins or arteries (types of blood vessels), including stroke, heart attack, or change in vision
•
have any bleeding problems
•
have a history of heart problems, including heart failure
•
have an unhealed wound
•
plan to have surgery or have had a recent surgery. You should stop taking INLYTA for at least 2 days before planned surgery. See "What are the possible side effects of INLYTA?"

For females, tell your healthcare provider if you:

•
are pregnant or plan to become pregnant. Taking INLYTA during pregnancy can harm your unborn baby. You should not become pregnant during treatment with INLYTA.
•
are able to become pregnant. You should have a pregnancy test before you start treatment with INLYTA. Use effective birth control during treatment and for 1 week after your last dose of INLYTA. Talk to your healthcare provider about birth control methods that you can use to prevent pregnancy during this time.
•
are breastfeeding or plan to breastfeed. It is not known if INLYTA passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after your last dose of INLYTA.

For males with female partners who are able to become pregnant:

•
Use effective birth control during treatment and for 1 week after your last dose of INLYTA.
•
If your female partner becomes pregnant during your treatment with INLYTA, tell your healthcare provider right away.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INLYTA and certain other medicines can affect each other causing serious side effects.
Talk with your healthcare provider before you start taking any new medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Find INLYTA® medical information:

Find INLYTA® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

INLYTA® Quick Finder

Medication Guide

Health Professional Information

What is INLYTA?

What is INLYTA?

•
in combination with avelumab or pembrolizumab as your first treatment.
•
alone when 1 prior drug treatment regimen for your RCC has not worked.

It is not known if INLYTA is safe and effective in children.

Before taking INLYTA, tell your healthcare provider about all of your medical conditions, including if you:

•
have high blood pressure
•
have thyroid problems
•
have liver problems
•
have a history of blood clots in your veins or arteries (types of blood vessels), including stroke, heart attack, or change in vision
•
have any bleeding problems
•
have a history of heart problems, including heart failure
•
have an unhealed wound
•
plan to have surgery or have had a recent surgery. You should stop taking INLYTA for at least 2 days before planned surgery. See "What are the possible side effects of INLYTA?"

For females, tell your healthcare provider if you:

•
are pregnant or plan to become pregnant. Taking INLYTA during pregnancy can harm your unborn baby. You should not become pregnant during treatment with INLYTA.
•
are able to become pregnant. You should have a pregnancy test before you start treatment with INLYTA. Use effective birth control during treatment and for 1 week after your last dose of INLYTA. Talk to your healthcare provider about birth control methods that you can use to prevent pregnancy during this time.
•
are breastfeeding or plan to breastfeed. It is not known if INLYTA passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after your last dose of INLYTA.

For males with female partners who are able to become pregnant:

•
Use effective birth control during treatment and for 1 week after your last dose of INLYTA.
•
If your female partner becomes pregnant during your treatment with INLYTA, tell your healthcare provider right away.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INLYTA and certain other medicines can affect each other causing serious side effects.
Talk with your healthcare provider before you start taking any new medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Prescribing Information
Download Prescribing Information

Health Professional Information

What is INLYTA?

What is INLYTA?

•
in combination with avelumab or pembrolizumab as your first treatment.
•
alone when 1 prior drug treatment regimen for your RCC has not worked.

It is not known if INLYTA is safe and effective in children.

Before taking INLYTA, tell your healthcare provider about all of your medical conditions, including if you:

•
have high blood pressure
•
have thyroid problems
•
have liver problems
•
have a history of blood clots in your veins or arteries (types of blood vessels), including stroke, heart attack, or change in vision
•
have any bleeding problems
•
have a history of heart problems, including heart failure
•
have an unhealed wound
•
plan to have surgery or have had a recent surgery. You should stop taking INLYTA for at least 2 days before planned surgery. See "What are the possible side effects of INLYTA?"

For females, tell your healthcare provider if you:

•
are pregnant or plan to become pregnant. Taking INLYTA during pregnancy can harm your unborn baby. You should not become pregnant during treatment with INLYTA.
•
are able to become pregnant. You should have a pregnancy test before you start treatment with INLYTA. Use effective birth control during treatment and for 1 week after your last dose of INLYTA. Talk to your healthcare provider about birth control methods that you can use to prevent pregnancy during this time.
•
are breastfeeding or plan to breastfeed. It is not known if INLYTA passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after your last dose of INLYTA.

For males with female partners who are able to become pregnant:

•
Use effective birth control during treatment and for 1 week after your last dose of INLYTA.
•
If your female partner becomes pregnant during your treatment with INLYTA, tell your healthcare provider right away.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INLYTA and certain other medicines can affect each other causing serious side effects.
Talk with your healthcare provider before you start taking any new medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.